Article thumbnail

Multidrug-resistance proteins are weak tumor associated antigens for colorectal carcinoma

By Christina S Mullins, Sven Eisold, Ernst Klar and Michael Linnebacher
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3160416
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2009). ABC transporters, drug resistance, and cancer stem cells.
  2. (2010). Bigner DD: MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
  3. (2010). Bigner DD: Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas.
  4. (2004). Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy. Cell Mol Immunol
  5. (2009). Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg Rev
  6. (2008). Drug Insight: panitumumab, a human EGFRtargeted monoclonal antibody with promising clinical activity in colorectal cancer. Nat Clin Pract Oncol
  7. (2005). Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood
  8. (2009). Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest
  9. (2008). H: Specificity in cancer immunotherapy. Semin Immunol
  10. (2010). Highdose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica
  11. (2008). ID: P-glycoprotein: so many ways to turn it on.
  12. (2006). IL: The cancer stem cell hypothesis: a work in progress. Lab Invest
  13. (2006). JC: Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother
  14. (2010). Klar E: Identification of an MSI-H tumor-specific cytotoxic T cell epitope generated by the (-1) frame of U79260(FTO).
  15. (2000). LD: Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs.
  16. (1999). LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity
  17. (2004). Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood
  18. (2007). Markers of chemoradiation resistance in patients with locally advanced head and neck squamous cell carcinoma, treated by intra-arterial carboplatin and concurrent radiation. Acta Otorhinolaryngol Ital
  19. (2009). Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res
  20. (2007). Melief CJ: Identification of T-cell epitopes for cancer immunotherapy. Leukemia
  21. (1999). MJ: A rapid and sensitive approach to mutation detection using real-time polymerase chain reaction and melting curve analyses, using BRCA1 as an example. Mol Diagn
  22. (2000). MJ: Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci
  23. (2001). Multidrug resistanceassociated protein 3 is a tumor rejection antigen recognized by HLAA2402-restricted cytotoxic T lymphocytes. Cancer Res
  24. (1999). Oskar Alexander Bachor, Stefan Stevanovic: SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics
  25. (1993). Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem
  26. (2006). Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
  27. (2010). Quillien V: Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol
  28. (2011). R: HER2: biology, detection, and clinical implications. Arch Pathol Lab Med
  29. (2004). Roots I: Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes. Anal Biochem
  30. (2000). Salgaller ML: Dendritic cellbased immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res
  31. (2009). Scheibenbogen C: A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML
  32. (2001). T: Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res
  33. (2002). Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene
  34. (2001). The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol
  35. (2001). von Knebel Doeberitz M: Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens.